
Andrea De Censi, MD, director of the medical oncology unit at the National Hospital E.O. Ospedali Galliera–SC Oncologia Medica in Genoa, Italy, discusses the hope for biosimilars in the United States.

Andrea De Censi, MD, director of the medical oncology unit at the National Hospital E.O. Ospedali Galliera–SC Oncologia Medica in Genoa, Italy, discusses the hope for biosimilars in the United States.

Andrea De Censi, MD, director of the medical oncology unit at the National Hospital E.O. Ospedali Galliera–SC Oncologia Medica in Genoa, Italy, discusses the results of the phase III TAM-01 trial in breast cancer.

Andrea De Censi, MD, director of the medical oncology unit at the National Hospital E.O. Ospedali Galliera–SC Oncologia Medica in Genoa, Italy, discusses the financial benefit of biosimilars in oncology.

December 14th 2018

September 12th 2019